Aurinia Q2 net income climbs 74% to $37.4 million; revenue rises 19% to $83.2 million - AUPH News | RalliesAurinia Q2 net income climbs 74% to $37.4 million; revenue rises 19% to $83.2 million
A
AUPH• Q2 financial results
- Aurinia Pharmaceuticals posted Q2 revenue of USD 83.2 million, up 19% from a year earlier.
- Net income climbed 74% to USD 37.4 million; diluted EPS rose 75% to USD 0.28.
- Operating cash flow increased 19% to USD 52.5 million; cash and investments totaled USD 443.1 million at June 30, 2026.
Clinical and guidance update
- Initiated the Phase 4 PRESERVE study evaluating LUPKYNIS in combination with biologics in lupus nephritis, targeting about 150 patients.
- Reiterated 2026 revenue guidance of USD 315 million to USD 325 million.
